Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Brown Advisory Inc.

Brown Advisory Inc. lessened its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 84.9% in the first quarter, according to its most recent filing with the SEC. The firm owned 2,219 shares of the medical research company’s stock after selling 12,506 shares during the quarter. Brown Advisory Inc.’s holdings in Charles River Laboratories International were worth $334,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Rothschild Investment LLC lifted its holdings in shares of Charles River Laboratories International by 480.0% in the first quarter. Rothschild Investment LLC now owns 174 shares of the medical research company’s stock valued at $26,000 after buying an additional 144 shares during the period. Optiver Holding B.V. acquired a new position in Charles River Laboratories International during the fourth quarter valued at $37,000. HM Payson & Co. acquired a new position in Charles River Laboratories International during the first quarter valued at $31,000. GeoWealth Management LLC raised its position in Charles River Laboratories International by 311.5% during the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock valued at $46,000 after buying an additional 190 shares during the period. Finally, Pilgrim Partners Asia Pte Ltd acquired a new position in Charles River Laboratories International in the 4th quarter worth about $48,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on CRL shares. Citigroup raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and upped their target price for the stock from $150.00 to $200.00 in a research report on Wednesday, July 9th. Redburn Atlantic raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and lowered their target price for the company from $188.00 to $182.00 in a research note on Friday, May 23rd. Wall Street Zen lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, July 5th. The Goldman Sachs Group downgraded Charles River Laboratories International from a “buy” rating to a “neutral” rating and lowered their target price for the company from $190.00 to $170.00 in a research report on Friday, March 21st. Finally, Evercore ISI boosted their price target on Charles River Laboratories International from $170.00 to $180.00 and gave the company an “outperform” rating in a research note on Wednesday, July 9th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of “Hold” and a consensus price target of $174.54.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $154.36 on Wednesday. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78. The firm’s fifty day simple moving average is $146.43 and its two-hundred day simple moving average is $151.17. The stock has a market capitalization of $7.58 billion, a P/E ratio of -237.48, a price-to-earnings-growth ratio of 5.35 and a beta of 1.49. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $254.15.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. The firm had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. During the same period last year, the firm posted $2.27 EPS. The business’s revenue was down 2.7% compared to the same quarter last year. As a group, analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of Charles River Laboratories International stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the transaction, the executive vice president directly owned 19,513 shares of the company’s stock, valued at $2,837,385.33. The trade was a 2.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).